A New Method for Determining Level of Immunosuppression in Humans
Description of Invention:
These inventions describe a method of determining the level of immunosuppression in a human subject by determining the level of expression of at least one selected T-Cell Receptor subunit protein, or protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in healthy individuals.
Applications:
The method can be used to identify candidates for autologous adoptive immunotherapy and for identification of agents which cause or reverse immunosuppression.
Development Status:
Pre-clinical stage
Inventors:
Augusto C. Ochoa et al. (NCI)
Patent Status:
DHHS Reference No. E-231-1995/1 --
U.S. Patent No. 5,583,002 issued 10 Dec 1996
DHHS Reference No. E-231-1995/3 --
U.S. Patent No. 5,556,763 issued 17 Sep 1996
U.S. Patent No. 5,889,143 issued 10 Dec 1996
U.S. Patent Application No. 09/280,655 filed 29 Mar 1999
DHHS Reference No. E-232-1995/0 --
U.S. Patent No. 5,658,744 issued 19 Aug 1997
DHHS Reference No. E-232-1995/1 --
U.S. Patent No. 5,965,366 issued 12 Dec 1999
and any foreign equivalent patents and patent applications
Licensing Status: Available for non-exclusive or exclusive licensing.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro Cancer -Therapeutics-Immunomodulators and Immunostimulants Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-5236
Email: stansbej@mail.nih.gov
Fax: (301) 402-0220
